Rhythm Pharmaceuticals ((RYTM)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Pharmaceuticals is conducting a study titled ‘A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Hypothalamic Obesity (HO).’ The study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of RM-718 in individuals with obesity and those with hypothalamic obesity. This research is significant as it explores potential treatments for obesity-related conditions, which are prevalent and challenging to manage.
The intervention being tested is RM-718, a drug administered via weekly subcutaneous injections. It is designed to assess the drug’s safety and effectiveness in both healthy obese individuals and patients with hypothalamic obesity.
The study is interventional and follows a randomized, parallel assignment model. It is triple-masked, meaning the participant, care provider, and investigator are unaware of the treatment assignments. The primary purpose of the study is treatment-focused.
The study began on March 5, 2024, with an estimated completion date yet to be announced. The latest update was submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This study update could influence Rhythm Pharmaceuticals’ stock performance positively, as successful results may enhance investor confidence and market positioning. The obesity treatment market is competitive, and advancements in this study could set Rhythm apart from its competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.